Fredun Pharmaceuticals Ltd
BSE:539730
Fredun Pharmaceuticals Ltd
BSE:539730
Price:
1 544
INR
-0.61%
Market Closed
Market Cap:
₹8.3B
Income Statement
Earnings Waterfall
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd
Income Statement
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd
Currency: INR
| Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||||||||||||||||||
| Interest Expense |
15
|
0
|
0
|
0
|
16
|
0
|
0
|
0
|
21
|
0
|
0
|
0
|
42
|
0
|
0
|
0
|
39
|
0
|
0
|
0
|
44
|
0
|
0
|
0
|
82
|
0
|
0
|
0
|
125
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
567
N/A
|
494
-13%
|
541
+10%
|
552
+2%
|
581
+5%
|
652
+12%
|
720
+10%
|
846
+17%
|
963
+14%
|
1 090
+13%
|
1 186
+9%
|
1 186
0%
|
1 128
-5%
|
983
-13%
|
1 005
+2%
|
1 198
+19%
|
1 316
+10%
|
1 654
+26%
|
1 866
+13%
|
1 952
+5%
|
2 217
+14%
|
2 275
+3%
|
2 418
+6%
|
2 655
+10%
|
2 743
+3%
|
2 867
+5%
|
2 997
+5%
|
3 086
+3%
|
3 466
+12%
|
3 648
+5%
|
3 902
+7%
|
4 060
+4%
|
4 538
+12%
|
4 949
+9%
|
5 328
+8%
|
5 910
+11%
|
|
| Gross Profit | |||||||||||||||||||||||||||||||||||||
| Cost of Revenue |
(372)
|
(307)
|
(360)
|
(369)
|
(422)
|
(478)
|
(505)
|
(591)
|
(636)
|
(753)
|
(887)
|
(916)
|
(853)
|
(729)
|
(715)
|
(889)
|
(1 064)
|
(1 365)
|
(1 564)
|
(1 616)
|
(1 834)
|
(1 844)
|
(1 960)
|
(2 166)
|
(2 174)
|
(2 266)
|
(2 359)
|
(2 387)
|
(2 740)
|
(2 881)
|
(3 026)
|
(3 133)
|
(3 474)
|
(3 748)
|
(4 026)
|
(4 402)
|
|
| Gross Profit |
195
N/A
|
187
-4%
|
181
-3%
|
184
+1%
|
159
-14%
|
173
+9%
|
215
+24%
|
254
+19%
|
327
+28%
|
337
+3%
|
299
-11%
|
269
-10%
|
275
+2%
|
254
-8%
|
290
+14%
|
310
+7%
|
251
-19%
|
289
+15%
|
302
+4%
|
336
+11%
|
384
+14%
|
431
+12%
|
457
+6%
|
489
+7%
|
570
+17%
|
601
+5%
|
637
+6%
|
699
+10%
|
725
+4%
|
767
+6%
|
875
+14%
|
927
+6%
|
1 064
+15%
|
1 200
+13%
|
1 302
+8%
|
1 508
+16%
|
|
| Operating Income | |||||||||||||||||||||||||||||||||||||
| Operating Expenses |
(154)
|
(168)
|
(162)
|
(151)
|
(129)
|
(156)
|
(182)
|
(200)
|
(232)
|
(228)
|
(201)
|
(194)
|
(209)
|
(196)
|
(216)
|
(214)
|
(178)
|
(215)
|
(221)
|
(243)
|
(267)
|
(295)
|
(309)
|
(313)
|
(317)
|
(332)
|
(330)
|
(363)
|
(382)
|
(399)
|
(465)
|
(490)
|
(589)
|
(665)
|
(691)
|
(773)
|
|
| Selling, General & Administrative |
(49)
|
(49)
|
(55)
|
(48)
|
(52)
|
(73)
|
(74)
|
(82)
|
(115)
|
(68)
|
(70)
|
(73)
|
(115)
|
(89)
|
(94)
|
(97)
|
(108)
|
(92)
|
(92)
|
(98)
|
(138)
|
(110)
|
(111)
|
(111)
|
(154)
|
(119)
|
(123)
|
(127)
|
(222)
|
(130)
|
(137)
|
(165)
|
(382)
|
(270)
|
(317)
|
(340)
|
|
| Research & Development |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(1)
|
0
|
(1)
|
(1)
|
0
|
0
|
(1)
|
(0)
|
(1)
|
0
|
(1)
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Depreciation & Amortization |
(11)
|
(12)
|
(13)
|
(13)
|
(13)
|
(15)
|
(14)
|
(14)
|
(13)
|
(13)
|
(16)
|
(18)
|
(19)
|
(19)
|
(19)
|
(20)
|
(20)
|
(20)
|
(21)
|
(21)
|
(22)
|
(23)
|
(25)
|
(27)
|
(28)
|
(31)
|
(33)
|
(35)
|
(38)
|
(39)
|
(41)
|
(42)
|
(50)
|
(54)
|
(62)
|
(69)
|
|
| Other Operating Expenses |
(94)
|
(107)
|
(95)
|
(89)
|
(65)
|
(67)
|
(94)
|
(104)
|
(104)
|
(147)
|
(115)
|
(103)
|
(75)
|
(87)
|
(102)
|
(98)
|
(50)
|
(102)
|
(108)
|
(123)
|
(107)
|
(161)
|
(171)
|
(175)
|
(134)
|
(183)
|
(174)
|
(200)
|
(122)
|
(230)
|
(288)
|
(283)
|
(157)
|
(341)
|
(312)
|
(364)
|
|
| Operating Income |
41
N/A
|
19
-54%
|
19
-2%
|
33
+76%
|
29
-10%
|
17
-41%
|
33
+91%
|
54
+64%
|
95
+75%
|
108
+15%
|
98
-10%
|
75
-23%
|
66
-13%
|
58
-12%
|
74
+27%
|
95
+29%
|
73
-23%
|
74
+1%
|
81
+9%
|
94
+16%
|
117
+25%
|
136
+16%
|
148
+9%
|
176
+18%
|
253
+44%
|
269
+6%
|
307
+14%
|
336
+9%
|
343
+2%
|
368
+7%
|
410
+11%
|
438
+7%
|
475
+9%
|
536
+13%
|
611
+14%
|
735
+20%
|
|
| Pre-Tax Income | |||||||||||||||||||||||||||||||||||||
| Interest Income Expense |
(18)
|
(19)
|
(21)
|
(22)
|
(18)
|
(19)
|
(15)
|
(16)
|
(28)
|
(40)
|
(46)
|
(50)
|
(41)
|
(39)
|
(39)
|
(41)
|
(39)
|
(40)
|
(42)
|
(42)
|
(32)
|
(58)
|
(53)
|
(60)
|
(68)
|
(85)
|
(108)
|
(125)
|
(118)
|
(145)
|
(169)
|
(183)
|
(193)
|
(250)
|
(274)
|
(330)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(6)
|
0
|
0
|
0
|
6
|
0
|
0
|
(12)
|
(12)
|
(12)
|
(12)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
|
| Total Other Income |
(1)
|
19
|
23
|
11
|
15
|
18
|
16
|
17
|
(5)
|
2
|
4
|
18
|
0
|
4
|
0
|
(17)
|
9
|
14
|
14
|
14
|
1
|
16
|
16
|
16
|
(9)
|
19
|
19
|
19
|
(10)
|
6
|
6
|
6
|
(6)
|
25
|
25
|
25
|
|
| Pre-Tax Income |
22
N/A
|
19
-14%
|
21
+9%
|
22
+3%
|
26
+22%
|
16
-41%
|
33
+112%
|
48
+46%
|
62
+28%
|
70
+14%
|
56
-20%
|
49
-12%
|
25
-50%
|
23
-8%
|
22
-2%
|
26
+14%
|
32
+25%
|
36
+13%
|
53
+47%
|
65
+23%
|
86
+32%
|
95
+10%
|
112
+18%
|
132
+18%
|
175
+32%
|
203
+16%
|
218
+8%
|
230
+5%
|
215
-7%
|
229
+7%
|
247
+8%
|
261
+6%
|
275
+5%
|
310
+13%
|
361
+17%
|
430
+19%
|
|
| Net Income | |||||||||||||||||||||||||||||||||||||
| Tax Provision |
(8)
|
(7)
|
(8)
|
(8)
|
(9)
|
(8)
|
(7)
|
(7)
|
(17)
|
(17)
|
(17)
|
(17)
|
(6)
|
(6)
|
(6)
|
(6)
|
(12)
|
(13)
|
(20)
|
(27)
|
(23)
|
(25)
|
(29)
|
(34)
|
(67)
|
(80)
|
(88)
|
(92)
|
(58)
|
(55)
|
(70)
|
(73)
|
(78)
|
(86)
|
(53)
|
(71)
|
|
| Income from Continuing Operations |
14
|
12
|
13
|
14
|
18
|
8
|
26
|
41
|
45
|
53
|
39
|
32
|
19
|
17
|
17
|
20
|
20
|
23
|
33
|
39
|
63
|
70
|
83
|
98
|
108
|
123
|
130
|
138
|
156
|
174
|
177
|
188
|
197
|
224
|
308
|
360
|
|
| Net Income (Common) |
14
N/A
|
12
-17%
|
13
+9%
|
14
+5%
|
18
+29%
|
8
-57%
|
26
+243%
|
41
+59%
|
45
+9%
|
53
+19%
|
39
-26%
|
32
-18%
|
19
-41%
|
17
-10%
|
17
-3%
|
20
+19%
|
20
+2%
|
23
+14%
|
33
+44%
|
39
+16%
|
63
+64%
|
70
+10%
|
83
+19%
|
98
+19%
|
108
+10%
|
123
+13%
|
130
+6%
|
138
+6%
|
156
+13%
|
174
+11%
|
177
+2%
|
188
+6%
|
197
+5%
|
224
+13%
|
308
+38%
|
360
+17%
|
|
| EPS (Diluted) |
6.07
N/A
|
4.95
-18%
|
5.41
+9%
|
5.66
+5%
|
7.44
+31%
|
3.12
-58%
|
6.42
+106%
|
10.22
+59%
|
11.59
+13%
|
13.32
+15%
|
9.86
-26%
|
8.13
-18%
|
4.77
-41%
|
4.23
-11%
|
4.14
-2%
|
4.94
+19%
|
5.05
+2%
|
5.78
+14%
|
8.32
+44%
|
8.69
+4%
|
14.23
+64%
|
15.61
+10%
|
18.63
+19%
|
21.82
+17%
|
22.93
+5%
|
26.75
+17%
|
27.84
+4%
|
29.4
+6%
|
33.24
+13%
|
36.93
+11%
|
37.46
+1%
|
39.79
+6%
|
42.52
+7%
|
47.39
+11%
|
65.24
+38%
|
76.13
+17%
|
|
Switch to:
Switch to:
See Also
Discover More
